Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: Guidance from the European Centre for Disease Prevention and Control
Magiorakos, A.P., Burns, K., Rodríguez Baño, J., Borg, M., Daikos, G., Dumpis, U., Lucet, J.C., Moro, M.L., Tacconelli, E., Simonsen, G.S., Szilágyi, E., Voss, A., Weber, J.T.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.